Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Industry Presents NHI Pricing System Reform Proposals to Health Minister
July 23, 2007
- Cook Conducts Joint Clinical Trial of Zilver PTX Stent in Japan and US
July 23, 2007
- GENERICS NEWS IN BRIEF
July 23, 2007
- Asahi Kasei Medical, Kuraray Medical to Merge Dialysis Business First
July 23, 2007
- Increases in DPC Hospitals Drive Nichi-Iko's Business
July 23, 2007
- MEDICAL DEVICE NEWS IN BRIEF
July 23, 2007
- Nippon Chemiphar to Drastically Shift Priority to Generics
July 23, 2007
- Number of Patients Enrolled in Avastin PMS Exceeds 500 in 1 Month: Chugai
July 23, 2007
- BUSINESS NEWS IN BRIEF
July 23, 2007
- Expenditures under NHI Programs in 2006 Rose Only 0.5%
July 16, 2007
- R&D NEWS IN BRIEF
July 16, 2007
- Draft Guidance for MD Studies Presented
July 16, 2007
- 420 Generics Receive NHI Price Listing
July 16, 2007
- Astellas, Kyoto Univ. Start Collaborative Drug Discovery
July 16, 2007
- 10 APIs Recommended for Approval by CDFS's Dept. on Drugs
July 16, 2007
- AntiCancer Inc. Opens Bioimaging Research Lab in Osaka
July 16, 2007
- BUSINESS NEWS IN BRIEF
July 16, 2007
- REGULATORY NEWS IN BRIEF
July 16, 2007
- Banyu's Preminent Shows Highest Awareness Rate: Survey
July 16, 2007
- Ryukaikon to Focus on Business Between Makers and Wholesalers
July 16, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…